Free tool
FAERS Monitor: Zituvimet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216743 or its brand name (Zituvimet, Metformin Hydrochloride, Sitagliptin). Reports on generic versions are filed under their own applications.
Reports
40
Serious
26
65% of reports
Hospitalization
10
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6
- completed suicide4
- dizziness4
- pain in extremity4
- abnormal dreams3
- diarrhoea3
- malaise3
- nausea3
- somnolence3
- anxiety2
- blood bilirubin increased2
- blood creatinine increased2
- blood glucose increased2
- decreased appetite2
- gamma-glutamyltransferase increased2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 13 |
| 2012 | 21 |
| 2025 | 1 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abnormal dreamsSignal | 3 | 57.1 | 19.2 | 114 |
| gamma-glutamyltransferase increased | 2 | 47.5 | 12.3 | 50 |
| blood bilirubin increased | 2 | 38.9 | 10.1 | 41 |
| completed suicideSignal | 4 | 25.2 | 10.0 | 71 |
| blood creatinine increased | 2 | 16.1 | 4.2 | 15 |
| somnolenceSignal | 3 | 7.8 | 2.6 | 12 |
| pain in extremitySignal | 4 | 7.1 | 2.8 | 16 |
| blood glucose increased | 2 | 5.6 | 1.4 | 4 |
| decreased appetite | 2 | 4.5 | 1.2 | 3 |
| dizzinessSignal | 4 | 4.2 | 1.7 | 7 |
| anxiety | 2 | 3.7 | 1.0 | 2 |
| malaise | 3 | 3.6 | 1.2 | 3 |
| diarrhoea | 3 | 2.4 | 0.8 | 1 |
| drug ineffective | 6 | 2.4 | 1.1 | 4 |
| nausea | 3 | 2.0 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.